Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Binding of 8‐methoxypsoralen to human serum proteins and red blood cells

Binding of 8‐methoxypsoralen to human serum proteins and red blood cells SUMMARY Serum binding of 8‐methoxypsoralen (8‐MOP) was studied by equilibrium dialysis. In therapeutic concentrations, 8‐MOP binding in serum was high, 91·4%, and constant, indicating concentration‐independent kinetics. This binding involved the two main proteins, human serum albumin and α‐acid glycoprotein, in a saturable process with one class of binding sites (n) and affinity constants (Ka) of 1·295 × 104 mol/1 and 2·115 × 104 mol/1, respectively. Binding to lipoproteins and · globulins was negligible and non‐saturable in therapeutic concentrations, with nKa values of 0·35,0·024,0·013 and 0·0004/μmol/1s for VLDL, LDL, HDL and γ globulins, respectively. Inhibition of 8‐MOP serum binding was observed with salicylic acid and indomethacin, but not with diazepam, warfarin or erythromycin. Over a range of therapeutic concentrations, the ratio of 8‐MOP concentration in red blood cells (RBCs) and in serum was constant at 20·3% and three times higher than would be expected if a simple diffusion of the 8‐MOP plasma free fraction (fu) occurred. According to the measured and calculated parameters, simulations of 8‐MOP blood binding in pathological states (hypoalbuminaemia with or without inflammation) showed variations of fu which were partially ‘buffered’ by RBCs. Simulation of 8‐MOP protein binding at cutaneous interstitial fluid level showed that fu is approximately 30% and permitted prediction of a decrease of fu available to the epidermis in case of local or systemic inflammation. This may imply an increase in the minimum phototoxic dose relevant for PUVA and explain some cases of ‘poor’ responsiveness of psoriatic patients to PUVA therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Dermatology Wiley

Binding of 8‐methoxypsoralen to human serum proteins and red blood cells

Download PDF
10 pages

Loading next page...
 
/lp/wiley/binding-of-8-methoxypsoralen-to-human-serum-proteins-and-red-blood-TPViulZIP7

References (17)

Publisher
Wiley
Copyright
Copyright © 1987 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0007-0963
eISSN
1365-2133
DOI
10.1111/j.1365-2133.1987.tb04118.x
Publisher site
See Article on Publisher Site

Abstract

SUMMARY Serum binding of 8‐methoxypsoralen (8‐MOP) was studied by equilibrium dialysis. In therapeutic concentrations, 8‐MOP binding in serum was high, 91·4%, and constant, indicating concentration‐independent kinetics. This binding involved the two main proteins, human serum albumin and α‐acid glycoprotein, in a saturable process with one class of binding sites (n) and affinity constants (Ka) of 1·295 × 104 mol/1 and 2·115 × 104 mol/1, respectively. Binding to lipoproteins and · globulins was negligible and non‐saturable in therapeutic concentrations, with nKa values of 0·35,0·024,0·013 and 0·0004/μmol/1s for VLDL, LDL, HDL and γ globulins, respectively. Inhibition of 8‐MOP serum binding was observed with salicylic acid and indomethacin, but not with diazepam, warfarin or erythromycin. Over a range of therapeutic concentrations, the ratio of 8‐MOP concentration in red blood cells (RBCs) and in serum was constant at 20·3% and three times higher than would be expected if a simple diffusion of the 8‐MOP plasma free fraction (fu) occurred. According to the measured and calculated parameters, simulations of 8‐MOP blood binding in pathological states (hypoalbuminaemia with or without inflammation) showed variations of fu which were partially ‘buffered’ by RBCs. Simulation of 8‐MOP protein binding at cutaneous interstitial fluid level showed that fu is approximately 30% and permitted prediction of a decrease of fu available to the epidermis in case of local or systemic inflammation. This may imply an increase in the minimum phototoxic dose relevant for PUVA and explain some cases of ‘poor’ responsiveness of psoriatic patients to PUVA therapy.

Journal

British Journal of Dermatology – Wiley

Published: Aug 1, 1987

There are no references for this article.